Read by QxMD icon Read

SCC Head and Neck

Imelda Seminerio, Géraldine Descamps, Sophie Dupont, Lisa de Marrez, Jean-Alexandre Laigle, Jérôme R Lechien, Nadège Kindt, Fabrice Journe, Sven Saussez
Head and Neck Squamous Cell Carcinomas (HNSCC) are characterized by a large heterogeneity in terms of the location and risk factors. For a few years now, immunotherapy seems to be a promising approach in the treatment of these cancers, but a better understanding of the immune context could allow to offer a personalized treatment and thus probably increase the survival of HNSCC patients. In this context, we evaluated the infiltration of FoxP3+ Tregs on 205 human formalin-fixed paraffin-embedded HNSCC and we assessed its prognostic value compared to other potential prognostic factors, including HPV infection...
February 15, 2019: Cancers
Patrick Wald, John Grecula, Steve Walston, Lai Wei, Aashish Bhatt, Douglas Martin, Marcelo Bonomi, James Rocco, Matthew Old, Theodoros Teknos, Dukagjin Blakaj
BACKGROUND: To report our institutional experience with intraoperative radiotherapy for persistent or recurrent head and neck cancer. METHODS: Sixty-one patients were treated with salvage surgery and intraoperative radiation therapy (IORT). Fifty-eight patients (95%) had previously received external beam radiotherapy (EBRT) as a component of their definitive therapy. Forty-four patients (72%) had squamous cell carcinoma (SCC). Surgical margins were positive in 28 patients (46%)...
February 19, 2019: Head & Neck
Andrew B Tassler, William E Gooding, Robert L Ferris
BACKGROUND: Organ preservation protocols have increasingly been applied for the treatment of head and neck cancers, including hypopharyngeal squamous cell carcinoma (HSCC). We sought to evaluate whether patients treated with primary surgery followed by adjuvant therapy had survival benefit over patients treated with initial nonsurgical modalities. METHODS: We retrospectively reviewed patients with new diagnosis of HSCC at the University of Pittsburgh (1994-2014) treated with either primary total laryngectomy with pharyngectomy or organ preservation...
February 19, 2019: Head & Neck
Matthew E Barclay, Georgios Lyratzopoulos, Fiona M Walter, Sarah Jefferies, Michael D Peake, Robert C Rintoul
BACKGROUND: Lung cancer 5-year survival has doubled over 15 years. Although the risk of second primary cancer is recognised, quantification over time is lacking. We describe the incidence of second and higher order smoking-related primary cancers in lung cancer survivors, identifying high-incidence groups and how incidence changes over time from first diagnosis. METHODS: Data on smoking-related primary cancers (lung, laryngeal, head and neck, oesophageal squamous cell carcinoma and bladder) diagnosed in England between 2000 and 2014 were obtained from Public Health England National Cancer Registration and Analysis Service...
February 18, 2019: Thorax
Adaia Valls-Ontañón, Javier Hernández-Losa, Rosa Somoza Lopez de Haro, Beatriz Bellosillo-Paricio, Santiago Ramón Y Cajal, Coro Bescós-Atín, Montserrat Munill-Ferrer, Margarita Alberola-Ferranti
BACKGROUND AND OBJECTIVES: Although there is scientific evidence demonstrating causation of human papilloma virus (HPV) on squamous cell carcinoma of head and neck, its percentage of causality on the anatomic region remains in dispute. This study was developed with the objectives of evaluating the relationship between HPV and oral and oropharyngeal squamous cell carcinomas (OOSCC), and of studying the correlation between HPV detection tests (PCR and p16). MATERIAL AND METHOD: Retrospective study of patients treated for OOSCC during 2011, with a follow-up of 6 years...
March 1, 2019: Medicina Clínica
Leilei He, Lixia Gao, Chloe Shay, Liwei Lang, Fenglin Lv, Yong Teng
BACKGROUND: A promising arsenal of histone deacetylase (HDAC)-targeted treatment has emerged in the past decade, as the abnormal targeting or retention of HDACs to DNA regulatory regions often occurs in many cancers. Head and neck squamous cell carcinoma (HNSCC) is one of the most aggressive malignancies worldwide associated with poor overall survival in late-stage patients. HDAC inhibitors have great potential to treat this devastating disease; however, few has been studied regarding the beneficial role of HDAC inhibition in anti-HNSCC therapy and the underlying molecular mechanisms remain elusive...
February 18, 2019: Journal of Experimental & Clinical Cancer Research: CR
Celine Bourgier, Anne Auperin, Sofia Rivera, Pierre Boisselier, Benoit Petit, Philippe Lang, Nathalie Lassau, Patrice Taourel, Raphael Tetreau, David Azria, Jean Bourhis, Eric Deutsch, Marie-Catherine Vozenin
PURPOSE: The "xxx" phase II trial (NCTxxx) assessed the efficacy of pravastatin as anti-fibrotic agent in patients with established cutaneous and subcutaneous radiation-induced fibrosis (RIF) after head and neck squamous cell carcinoma (HNSCC) radiotherapy and/or radio-chemotherapy. METHODS AND MATERIALS: The main inclusion criteria were: patients with HNSCC in remission, with grade ≥2 cutaneous and subcutaneous neck RIF (NCI-CTCAE v4.0); no current treatment with statins or fibrates...
February 15, 2019: International Journal of Radiation Oncology, Biology, Physics
Yashoda Ghanekar, Subhashini Sadasivam
Background: Sequencing studies across multiple cancers continue to reveal mutations and genes involved in the pathobiology of these cancers. Exome sequencing of oral cancers, a subset of Head and Neck Squamous cell Carcinomas (HNSCs) common among tobacco-chewing populations, revealed that ∼34% of the affected patients harbor mutations in the CASP8 gene . Uterine Corpus Endometrial Carcinoma (UCEC) is another cancer where ∼10% cases harbor CASP8 mutations. Caspase-8, the protease encoded by CASP8 gene, plays a dual role in programmed cell death, which in turn has an important role in tumor cell death and drug resistance...
2019: PeerJ
Jessica L Geiger, Jamie A Ku
Despite an overall decline in the incidence of tobacco-related cancers, human papillomavirus (HPV)-related head and neck squamous cell carcinoma (HNSCC) of the oropharynx is on the rise. The prognosis of HPV-related oropharynx cancer (HPV-OPC) is generally favorable even in locoregionally advanced disease, and a variety of treatment options are available. Though the primary treatment modality of choice remains definitive radiation (RT), surgical resection followed by appropriate adjuvant therapy remains an option, especially in those patients who may not be favorable candidates for definitive radiotherapy, particularly when concurrent chemotherapy is warranted...
February 15, 2019: Current Treatment Options in Oncology
Vaishnavi Sambandam, Mitchell J Frederick, Li Shen, Pan Tong, Xiayu Rao, Shaohua Peng, Ratnakar Singh, Tuhina Mazumdar, Chenfei Huang, Qiuli Li, Curtis R Pickering, Jeffrey N Myers, Jing Wang, Faye M Johnson
PURPOSE: Head and neck squamous cell carcinoma (HNSCC) is driven largely by the loss of tumor suppressor genes, including NOTCH1, but lacks a biomarker-driven targeted therapy. Although the PI3K/mTOR pathway is frequently altered in HNSCC, the disease has modest clinical response rates to PI3K/mTOR inhibitors and lacks validated biomarkers of response. We tested the hypothesis that an unbiased pharmacogenomics approach to PI3K/mTOR pathway inhibitors would identify novel, clinically relevant molecular vulnerabilities in HNSCC with loss of tumor suppressor function...
February 15, 2019: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Yuexiang Qin, Juncheng Wang, Gangcai Zhu, Guo Li, Haolei Tan, Changhan Chen, Leiming Pi, Li She, Xiyu Chen, Ming Wei, Zhexuan Li, Zhifeng Liu, Donghai Huang, Yong Liu, Xin Zhang
Metastasis is one of the primary causes for high mortality in patients with squamous cell carcinoma of the head and neck (SCCHN). Our previous study showed that chemokine (C-C motif) ligand 18 (CCL18), derived from tumour-associated macrophages (TAMs), regulates SCCHN metastasis by promoting epithelial-mesenchymal transition (EMT) and preserving stemness. However, the underlying mechanism needs to be further investigation. Interestingly, metadherin (MTDH) expression was induced when SCCHN cells were stimulated with recombinant CCL18 protein in this study...
February 15, 2019: Journal of Cellular and Molecular Medicine
Val J Lowe, Fenghai Duan, Rathan M Subramaniam, JoRean D Sicks, Justin Romanoff, Twyla Bartel, Jian Q Michael Yu, Brian Nussenbaum, Jeremy Richmon, Charles D Arnold, David Cognetti, Brendan C Stack
PURPOSE: The objective of this study was to determine the negative predictive value (NPV) of positron emission tomography (PET)/computed tomography (CT) for the clinically N0 neck on the basis of neck dissection. METHODS: Participants with newly diagnosed, first-time, head and neck squamous cell carcinoma (HNSCC) and at least one clinically N0 neck side for which dissection was planned were included. A total of 287 participants were prospectively enrolled from 23 American College of Radiology Imaging Network-qualified institutions...
February 15, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
José F Gallegos-Hernández, José A Abrego-Vázquez, Aldo Olvera-Casas, Gerardo G Minauro-Muñoz, Alma L Ortiz-Maldonado
Introduction: Patients with bulky metastases of squamous cell carcinoma of the head and neck represent a challenge for the therapeutic decision; balance between oncological control and complications should be achieved. The therapeutic sequence has no impact on survival but sequelae. Objective: We analyze the oncological results in patients with bulky metastases on the neck treated with induction chemotherapy and with up-front neck dissection. Method: Retrospective analysis of patients undergoing treatment for cervical lymph node metastasis of squamous cell carcinoma; The therapeutic sequence was decided based on volume, resectability, site, and size of the primary and general condition of the patient...
2019: Cirugia y Cirujanos
Shyamji Rawat, Hemu Tandan, Sanandan Patel, Sameer Chaudhari
Context: Nimotuzumab is the only anti-epidermal growth factor receptor monoclonal antibody which can be safely added to concurrent chemoradiotherapy (CRT) to improve efficacy in the management of unresectable, locally advanced squamous cell carcinoma of head and neck (LA-SCCHN). However, the evidence available on this is limited. Aims: We retrospectively investigated efficacy and safety of nimotuzumab when combined with chemoradiation for LA-SCCHN. Settings and Design: Hospital records of 39 patients from January 2012 to December 2016 diagnosed with locally advanced (Stage III-IVb), unresectable SCCHN, and treated with concurrent CRT with weekly nimotuzumab were reviewed retrospectively after fulfilling the inclusion/exclusion criteria...
January 2019: South Asian Journal of Cancer
John Park, Veronica McPike, Suman Kambhampati, Chao Huang, January Fields-Meehan, Linda Verkruyse, Ace Allen, Eashwer Reddy
The rates of human papillomavirus positivity of the p16 biomarker in veterans were similar to those of patients with oropharyngeal head and neck tumors in the general population, but differed from general population patients with nonoropharyngeal squamous cell carcinoma.
August 2018: Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS
Tomoya Yokota
Recent breakthrough in cancer immunotherapy employing immune checkpoint inhibitors(ICI)has evolved into number of clinical trials with antibodies against PD-1, PD-L1, and CTLA-4 for patients with squamous cell carcinoma of head and neck (SCCHN). The development of ICI in SCCHN initiated in the recurrent and metastatic setting. CheckMate141 supports nivolumab as a standard therapy for patients with platinum-refractory recurrent and metastatic-SCCHN. KEYNOTE-048 testing pembrolizumab demonstrated future practice-changing data in platinum sensitive recurrent and metastatic-SCCHN...
January 2019: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Alfredo Cruz-Gregorio, Imelda Martínez-Ramírez, José Pedraza-Chaverri, Marcela Lizano
Head and neck cancer (HNC) is the sixth cause of cancer-related death worldwide. Head and neck squamous cells carcinoma (HNSCC) is the most frequent subtype of HNC. The development of HNSCC is associated to alcohol consumption, smoking or infection by high-risk human Papillomavirus (HR-HPV). Although the incidence of cancers associated with alcohol and tobacco has diminished, HNSCC associated with HR-HPV has significantly increased in recent years. However, HPV-positive HNSCC responds well to treatment, which includes surgery followed by radiation or chemoradiation therapy...
February 5, 2019: Cancers
Stella Chin-Shaw Tsai, Jing-Yang Huang, Chuck Lin, Yung-Po Liaw, Frank Cheau-Feng Lin
Human papillomavirus (HPV) has been linked with development of oropharyngeal squamous cell carcinoma, a subset of head and neck cancer (HNC). This study aimed to evaluate the association between HPV infection and subsequent development of HNC and to report epidemiological information in Taiwan.This population-based cohort study retrieved patient data from the longitudinal health insurance database (LHID) of Taiwan's National Health Insurance Research Database (NHIRD) from 2005 to 2010 and analyzed it retrospectively...
February 2019: Medicine (Baltimore)
Lin Li, Zhen Dong, Jie Yang, Qian Li, Qian Lei, Jingxin Mao, Liqun Yang, Hongjuan Cui
As a member of the Sirtuins family in mammals, SIRT7 locates in nucleus and is a highly specific H3K18Ac (acetylated lysine 18 of histone H3) deacetylase. Recent studies showed that SIRT7 could participate in the ribosomal RNA transcription, cell metabolism, cell stress and DNA damage repair through various signaling pathways. In addition, SIRT7 is also closely related with aging, heart disease and fatty liver. In particular, SIRT7 plays important roles in the regulation of initiation and development of various tumors, such as liver cancer, gastric cancer, breast cancer, bladder cancer, colorectal cancer, and head/neck squamous cell carcinoma...
January 25, 2019: Sheng Wu Gong Cheng Xue Bao, Chinese Journal of Biotechnology
Toshiya Maebayashi, Naoya Ishibashi, Takuya Aizawa, Masakuni Sakaguchi, Tsutomu Saito, Jiro Kawamori, Yoshiaki Tanaka, Yukari Hirotani, Taku Homma
PURPOSE: Treatment guidelines have not been established for unknown primary head and neck squamous cell carcinoma (SCC). For these patients, chemoradiotherapy (CRT) can provide a better prognosis than that for patients with other head and neck cancers. The presence of HPV in the tumor is associated with a better outcome. However, not all patients with HPV-positive unknown primary head and neck SCC experience good treatment outcomes in actual clinical settings. METHODS: We thus retrospectively determined the Ki-67 proliferation index and p16 expression status to assess the associations of these parameters with treatment outcomes of patients with unknown primary head and neck SCC...
February 12, 2019: European Archives of Oto-rhino-laryngology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"